Full text is available at the source.
Abstract
The gut microbiome may significantly influence the efficacy and toxicity of immune checkpoint inhibitors (ICIs) in cancer therapy.
- Gut microbiome is associated with immune modulation and plays a crucial role in human health and disease.
- Some cancer patients experience limited response or adverse effects from ICIs, highlighting variability in treatment outcomes.
- Modulating the gut microbiome may improve therapeutic responses and reduce treatment-related toxicities of cancer immunotherapy.
- The review discusses the relationship between gut microbiome and cancer immunotherapy, focusing on efficacy and toxicity.
- Approaches for manipulating gut microbiome to enhance responses to ICIs are explored, alongside current challenges.
Simplified